IDWeek 2023

IDWeek 2023
October 11-16, 2023

Infectious Diseases Society of America: ID Week 2023.

Explore more information for Gilead HIV / AIDS therapies
Results (14)

Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) during The COVID-19 Pandemic

The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US

Antiretroviral Treatment (ART) Packaging Preferences and Their Impact on Adherence Among People With HIV (PWH): Findings From a Best-Worst Scaling Survey

Weight and Metabolic Changes after using Long-Acting Lenacapavir in a Combination Regimen in Treatment Naïve PWH

Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 104 results

Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations

Remdesivir and Obeldesivir Retain Potent Activity Against SARS-COV-2 Omicron Variants

Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19

Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies

Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir

Drug-Drug Interaction Profiling of Obeldesivir; A Promising Oral Treatment for COVID-19

Clinical Evaluation of Drug-Drug Interactions with Remdesivir

Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG)-based 3-drug regimens in adults with HIV who have suboptimal antiretroviral adherence